Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

FDA OKs New Videx Formulation

By Ernie Rodriguez
 From AIDS Project Los Angeles

December 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

A new 200 mg formulation of Videx (ddI, didanosine) to be used once a day has been approved by the Food and Drug Administration and is expected to be available in December.

People with HIV infection can now take two tablets once a day as opposed to the current formulation which calls for two tablets twice a day. Videx is the first nucleoside reverse transcriptase inhibitor on the market to be used once daily.

Since the dosing is now once a day, better adherence to this medication is expected.

Advertisement
A buffer in the old Videx formulation helped with absorption of the drug and required that it be taken half an hour before a meal or an hour after a meal. Because the prior formulation of Videx caused gastrointestinal (GI) problems, this has been a problem for some. The new formulation, however, includes less of the buffer since the chemical composition of the drug has been changed. Fewer GI problems are expected to be associated with the new formulation.


This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
 
See Also
More on the FDA Drug Approval Process and Other Regulatory Issues

 

Advertisement